Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
Assessment of Serum Level of Interleukin-15 and Interferon Gamma in Alopecia Areata Patients Before and After Baricitinib Treatment
In the register
The register attaches this trial to Baricitinib (Olumiant) (Eli Lilly), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Benha University
- Participants (registry)
- 20
- Start
- January 2023
- Primary completion
- January 2024
- Study completion
- June 2026
- Last registry update
- June 2026
- Countries
- Egypt
Conditions studied: Alopecia Areata
Interventions: Baricitinib 4 MG Oral Tablet
Other trials of Baricitinib (Olumiant)
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.